Skip to content
Tokyo Brief東 京 ブ リ ー フJapan's day, wrapped and delivered by morning.
Company
Companies

SymBio Pharmaceuticals

シンバイオ製薬

4582 · TSE · Pharmaceutical · 2 articles

Financials Consolidated

Revenue¥1.31bn−46.7% year on yearConsolidated · FY12/25

Ordinary profit−¥4.65bnConsolidated · FY12/25

Net profit−¥4.78bnConsolidated · FY12/25

Performance over time

Revenue
¥10.0bnFY12/22
¥5.59bnFY12/23
¥2.45bnFY12/24
¥1.31bnFY12/25
Ordinary profit
¥2.00bnFY12/22
−¥736mFY12/23
−¥3.69bnFY12/24
−¥4.65bnFY12/25
Net profit (attributable)
¥1.18bnFY12/22
−¥1.96bnFY12/23
−¥3.83bnFY12/24
−¥4.78bnFY12/25
Op. cash flow
¥1.61bnFY12/22
−¥195mFY12/23
−¥3.42bnFY12/24
−¥4.58bnFY12/25

People & pay

Employees, whole group91 peopleFY12/25

Employees, parent company (non-consolidated)86 peopleFY12/25

Average salary¥13.8mFY12/25

Average salary is for the parent company's own employees (non-consolidated), as Japanese annual reports disclose it.

Five-year history
Five-year history
Fiscal yearRevenueOrdinary profitNet profit (attributable)EPSTotal assetsNet assetsOp. cash flow
FY12/25¥1.31bn−46.7% year on year−¥4,648m−¥4.78bn−¥95.12¥3.87bn¥1.27bn−¥4,576m
FY12/24¥2.45bn−56.1% year on year−¥3,689m−¥3.83bn−¥85.00¥4.97bn¥4.20bn−¥3,417m
FY12/23¥5.59bn−44.1% year on year−¥736m−¥1.96bn−¥49.19¥8.17bn¥7.21bn−¥195m
FY12/22¥10.01bn¥2,000m¥1.18bn¥30.20¥10.43bn¥8.51bn¥1,614m

Per-share figures are as each report states them: a share split is restated only for the year before it, and dividends are as paid.

Figures from annual report S100XNE5 · Japan GAAP. Each figure's years come from one report's five-year summary.

Latest coverage

TSE:4582

  1. SymBio Secures Exclusive US Government License to Develop a Multiple Sclerosis Drug Candidate

    SymBio Pharmaceuticals has signed an exclusive global license with the US Department of Health and Human Services to develop brincidofovir against multiple sclerosis, but the programme remains in animal testing, and the company disclosed no financial terms while saying the deal will not affect its earnings forecast for the year ending December 2026.

  2. SymBio's ¥6.77bn EVO Fund Deal Could More Than Double Its Share Count

    SymBio Pharmaceuticals lined up an estimated ¥6.77bn from Cayman fund EVO Fund to keep its antiviral drug trials funded through March 2028, but the bond-and-warrant structure could swell its share count by more than 125% if every warrant is exercised.

5% holders

Latest disclosed holders and exits below 5%.

2 holders · data through

5% holders
HolderStakeChangePurposeFiling
Evo Fund45.60% own · 45.60% group of 2−3.33 ppPure investment
Read full ownership purposePure investment. No specific circumstances are assumed, but Filer No. 1 may, depending on the circumstances from time to time, provide appropriate advice to the issuer.
Machine translated
Original (Japanese)純投資。特定の状況は想定されていないが、第1提出者は発行者に対しその時々の状況に応じて適切な助言を行う場合がある。
Filed  — filing S100ZG8X
吉田 文紀6.35%+0.00 ppFounder, insider or familyThe filer is a representative director of the issuer and holds the shares for the purpose of continuing to hold them in order to stabilize management.Machine translated
Original (Japanese)発行会社の代表取締役であり、経営の安定化を図るための継続保有目的であります。
Filed  — filing S100YY0M